SSY Group (HK:2005) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
SSY Group Limited has successfully obtained approval from China’s National Medical Products Administration for its drug Nikethamide, a central nervous system stimulant used to treat respiratory depression. This development marks a significant step for the company as it enhances its product portfolio in the pharmaceutical market.
For further insights into HK:2005 stock, check out TipRanks’ Stock Analysis page.
